Q-omics provides the consensus-scored RNF157 profile across patient tissues and cancer cell-line models. RNF157 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RNF157 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, RNF157 RNA expression shows 18,775 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, LIHC, and TGCT as cancer lineages where RNF157 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF157 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF157 survival associations across molecular data types. RNF157 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF157 RNA expression–survival associations across cancer types. High RNF157 expression shows unfavorable associations in LUAD and LIHC, but favorable associations in KIRC, HNSC, PAAD and COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for RNF157 RNA expression.
This table summarizes RNF157 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNF157. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF157 shows lower tumor expression in THCA, HNSC and BRCA and higher tumor expression in LIHC, UCEC and LUAD. The LIHC box plot shows higher RNF157 RNA expression in tumor versus normal tissue (log2 FC = +2.044, t-test p < 0.001).
This table shows molecular features associated with RNF157 in patient tissues and cancer cell lines. In patient samples, RNF157 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF157 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
